Publication:
Epidemiological and clinical analysis of community-acquired Mycoplasma pneumonia in children from a Spanish population, 2010-2015

dc.contributor.authorAguilera-Alonso, David
dc.contributor.authorLopez Ruiz, Rocio
dc.contributor.authorCenteno Rubiano, Jose
dc.contributor.authorMorell Garcia, Daniel
dc.contributor.authorValero Garcia, Isabel
dc.contributor.authorOcete Mochon, Maria Dolores
dc.contributor.authorMontesinos Sanchis, Elena
dc.date.accessioned2024-09-10T13:08:53Z
dc.date.available2024-09-10T13:08:53Z
dc.date.issued2019-07
dc.description.abstractIntroduction and objectives: Mycoplasma pneumoniae (MP) is one of the most common etiological agents of community-acquired pneumonia (CAP) in children. We aimed to describe the clinical and epidemiological characteristics, treatment and outcome of children diagnosed with community-acquired MP pneumonia (CAMP) in a tertiary hospital in Valencia, Spain. Material and methods: Medical records of children <14 years with CAMP were retrospectively reviewed from January 2010 to December 2015. Patients with radiological evidence of pneumonia and microbiological confirmation of MP (PCR from nasopharyngeal swab and/or serum specific IgM) were considered CAMP. Results: One hundred and sixty two children were diagnosed with CAMP; median age 6 years (IQR: 4-9). The positive MP test rate among children with CAP progressively increased with age as did the empirical use of macrolides. There were two peaks of cases in 2011 and in 2015, being July, August, November and December the seasons with the higher number of cases. The most frequent radiological pattern was segmental infiltrate (62.3%) and 22 (13.6%) children had pleural effusion. It was noteworthy the mild symptomatology and low levels of inflammatory parameters that children with CAMP had. A macrolide was empirically initiated in 68.5% of cases. Hospital admission rate was inversely proportional to patient's age. Conclusions: According to this study, older, less symptomatic patients and with lower inflammatory parameters had the greatest rate of MP infection among children with CAP and thus they could benefit of empiric macrolide therapy. Therefore, knowing the epidemiology of a geographical area may be important for the management of CAP in children.en
dc.format.number1es_ES
dc.format.page21-29es_ES
dc.format.volume91es_ES
dc.identifier.citationAguilera-Alonso D, Lopez Ruiz R, Centeno Rubiano J, Morell Garcia M, Valero Garcia I, Ocete Mochon MD, et al. Epidemiological and clinical analysis of community-acquired Mycoplasma pneumonia in children from a Spanish population, 2010-2015. An Pediatr. 2019 Jul;91(1):44460. Epub 2019 Feb 6.en
dc.identifier.doi10.1016/j.anpedi.2018.07.016
dc.identifier.e-issn1696-4608es_ES
dc.identifier.issn1695-4033
dc.identifier.journalAnales de Pediatriaes_ES
dc.identifier.otherhttp://hdl.handle.net/20.500.13003/17439
dc.identifier.pubmedID32289046es_ES
dc.identifier.puiL2001481543
dc.identifier.scopus2-s2.0-85060191968
dc.identifier.urihttps://hdl.handle.net/20.500.12105/22696
dc.identifier.wos473262200004
dc.language.isoengen
dc.publisherElsevier
dc.relation.publisherversionhttps://dx.doi.org/10.1016/j.anpedi.2018.07.016en
dc.rights.accessRightsopen accessen
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectMycoplasma pneumoniae
dc.subjectCommunity-acquired pneumonia
dc.subjectCommunity-acquired Mycoplasma pneumonia
dc.subjectEpidemiology
dc.subjectMacrolides
dc.titleEpidemiological and clinical analysis of community-acquired Mycoplasma pneumonia in children from a Spanish population, 2010-2015en
dc.typeresearch articleen
dspace.entity.typePublication
relation.isPublisherOfPublication7d471502-7bd5-4f7a-90a4-8274382509ef
relation.isPublisherOfPublication.latestForDiscovery7d471502-7bd5-4f7a-90a4-8274382509ef

Files